TNBCDX® is the first genomic test designed specifically for patients with early-stage TNBC.
The test integrates clinical variables with key tumor and immune biological factors across 15 genes to provide a comprehensive risk assessment, guiding treatment decisions in a clinical setting.
TNBCDX® includes two scores: a risk score and a pCR (pathological complete response) likelihood score. Additionally, the test measures the levels of ERBB2 to ensure that the tumor is accurately classified as TNBC.
TNBCDX® is currently available in a Research Use Only (RUO) format. We are in the process of standardizing it, with plans to offer it commercially available by 2025.